DBV Technologies (DBVT) Projected to Release Earnings on Wednesday

DBV Technologies (NASDAQ:DBVT) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect DBV Technologies to post earnings of ($0.1564) per share and revenue of $0.74 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

DBV Technologies Stock Performance

DBVT opened at $9.98 on Tuesday. The stock’s 50 day moving average price is $11.96 and its 200-day moving average price is $17.11. DBV Technologies has a one year low of $8.63 and a one year high of $26.18. The stock has a market cap of $627.52 million, a price-to-earnings ratio of -2.84 and a beta of -1.04.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DBVT. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a report on Thursday, October 15th. Citizens Jmp increased their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 30th. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of DBV Technologies in a research report on Thursday, September 10th. Finally, Citigroup reiterated a “market outperform” rating on shares of DBV Technologies in a research report on Wednesday, September 30th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, DBV Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.